TITLE

Colesevelam HCI Improves Glycemic Control, Independent of Age, in Patients with Type 2 Diabetes Uncontrolled on Metformin, Sulfonylurea, or Insulin-Based Therapy

AUTHOR(S)
Ovalle, Fernando; Philis-Tsimikas, Athena; Truitt, Kenneth; Dmuchowski, Carl; Jones, Michael
PUB. DATE
June 2007
SOURCE
Diabetes;Jun2007 Supplement 1, Vol. 56, pA536
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article discusses studies which examined the effects of Colesevelam HC1 (COL), a bile acid sequestrant indicated to lower low-density lipoprotein cholesterol, versus placebo (PL) when combined with metformin, sulfonylurea or insulin-based therapy. A pilot study showed that COL improves the lipid profile and glycemic control when added to an established antidiabetic regimen in patients with type 2 diabetes mellitus (T2DM). Also reported is the analysis of glycemic control based on age.
ACCESSION #
25822401

 

Related Articles

  • Pramlintide Improved Glycemic Control Without Increased Risk of Hypoglycemia in Patients With Type 2 Diabetes Using Basal Insulin. Lutz, Karen; Maier, Holly; Zhang, Bei; Frias, Juan // Diabetes;Jun2007 Supplement 1, Vol. 56, pA143 

    Pramlintide (PRAM), an analog of the beta-cell hormone amylin, improves glycemic control and reduces weight in patients with diabetes using mealtime insulin. PRAM has been associated with an increased risk of insulin-induced severe hypoglycemia, particularly in patients with type 1 diabetes. The...

  • Inhaled Technosphere Insulin Versus Inhaled Technosphere Placebo in Insulin-Naïve Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetes Agents. Rosenstock, Julio; Franco, Denise; Korpachev, Vadym; Shumel, Brad; Ma, Yuhui; Baughman, Robert; Amin, Nikhil; McGill, Janet B.; Affinity 2 Study Group // Diabetes Care;Dec2015, Vol. 38 Issue 12, p2274 

    Objective: To investigate the efficacy and safety of prandial Technosphere inhaled insulin (TI), an inhaled insulin with a distinct time action profile, in insulin-naïve type 2 diabetes (T2D) inadequately controlled on oral antidiabetes agents (OADs).Research Design and...

  • The Effect of a Bile Acid Sequestrant on Glucose Metabolism in Subjects With Type 2 Diabetes. Smushkin, Galina; Sathananthan, Matheni; Piccinini, Francesca; Man, Chiara Dalla; Law, Jennie H.; Cobelli, Claudio; Zinsmeister, Alan R.; Rizza, Robert A.; Vella, Adrian // Diabetes;Apr2013, Vol. 62 Issue 4, p1094 

    We designed an experiment to examine the effect of bile acid sequestration with Colesevelam on fasting and postprandial glucose metabolism in type 2 diabetes. To do so, we tested the hypothesis that Colesevelam increases the disposition index (DI), and this increase is associated with increased...

  • Novel therapies for diabetes mellitus. PAPAZAFIROPOULOU, A. K.; KARDARA, M. S.; PAPPAS, S. I. // Archives of Hellenic Medicine / Arheia Ellenikes Iatrikes;Mar/Apr2012, Vol. 29 Issue 2, p187 

    This review paper summarizes currently available data on the development of newer categories of antidiabetic agents, their ways of action and their clinical importance. During recent years significant achievements have been made in this field, including the development of SGLT2 inhibitors and...

  • Balancing Risks in the Choice of Medications for Diabetics with Alcohol Use Disorders: Physicians Prefer Insulin and Sulfonylureas. Miller, Donald R.; Smith, Peter C.; Berlowitz, Dan R. // Diabetes;Jun2007 Supplement 1, Vol. 56, pA577 

    Deciding on a medical regimen for diabetes patients with an alcohol use disorder (AUD), clinicians must balance the risks of hypoglycemia from insulin and sulfonylureas with the risk of liver toxicity from thiazolidinediones (TZD) and lactic acidosis from metformin. We describe the medical...

  • Effect of insulin pen devices on the management of diabetes mellitus. Mecce, Jerry // American Journal of Health-System Pharmacy;6/1/2008, Vol. 65 Issue 11, p1076 

    The article reports on the effect of insulin pen devices to people with diabetes mellitus. The author points out that majority of patients with type 2 diabetes ultimately require therapy to maintain glycemic control. He emphasizes the importance of proper coordination among patient, physician...

  • Early Insulinization to Prevent Diabetes Progression. RAZ, ITAMAR; MOSENZON, OFRI // Diabetes Care;Aug2013 Supplement, Vol. 36 Issue S2, pS190 

    The article examines data collected from clinical studies on the role of early insulin treatment in the preservation of ß-cell function in patients with type 2 diabetes. Despite the safety and feasibility of early insulin therapy demonstrated in the ORIGIN study, the authors argue there are...

  • Exenatide. Keating, Gillian M. // Drugs;2005, Vol. 65 Issue 12, p1681 

    â–´ Exenatide is an incretin mimetic. It improves glycaemic control via various glucoregulatory mechanisms, including glucose-dependent insulinotropism, suppression of inappropriately high glucagon levels, delayed gastric emptying and reduction of food intake. â–´ In three large, well...

  • Statement of Retraction. Raz, Itamar // Diabetes Care;Jan2015, Vol. 38 Issue 1, p178 

    A retraction of the article "Treatment of Recent-Onset TYpe 1 Diabetic Patients with DiaPep277: Results of a Double-Blind, Placebo-Controlled, Randomized Phase 3 Trial," published in the 2014;37: 1392-1400 issue is presented.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics